Volume : 08, Issue : 05, May – 2021

Title:

29.INVESTIGATION OF CLINICAL PARAMETERS OF PATIENTS ADMITTED WITH COVID-19 PNEUMONIA AND MEDICATIONS USED TO TREAT THEIR CO – MORBIDITIES

Authors :

Syed Yasir Hussain and Ihsanullah Khan

Abstract :

There has already been further research into the risk factors and molecular mechanisms underlying Covid-19’s serious breathing involvement and reservations regarding nonsteroidal anti-inflammatory inhibitors (NSAIDs) and renin angiotensin-aldosterone (RAAS) have also arisen.
Objective: The purpose of this study was to determine whether there were any associations between medications taken on a regular basis for comorbid diseases prior to the diagnosis of Covid-19 pneumonia and demographic or clinical characteristics at admission.
Materials and Methods: Between March 11th and April 15th, 2020, patients diagnosed with pneumonia in emergency, internal medicine, and cardiology outpatient clinics were recruited, and their clinical and demographic characteristics, including blood tests, oxygen saturations (SO2), and degree of lung infiltration on computed tomography, were analysed in relation to the medications they took on a regular basis.
Results: Angiotensin converting enzyme inhibitors (ACE inh.) or angiotensin receptor blockers (ARB) users were significantly older than the no-ACE inh./ARB group and had significantly lower SO2 levels on admission, whereas NSAID users with Covid-19 exhibited a significant female predominance and lower haemoglobin levels than the no-NSAID group. Additionally, PPI users had a significant female predominance, were older in age, and had lower haemoglobin levels. Finally, antiaggregant users who used Covid-19 had a lower SO2 level upon admission, and overall, cases involving regular drug use were significantly associated with older age.
Conclusion: There were significant associations between demographic and clinical characteristics at the time of admission for Covid-19 pneumonia and the use of major drug classes, including RAAS inhibitors, NSAIDs, and proton pump inhibitors.
Key words: Proton pump inhibitors, Non-steroidal anti-inflammatory drugs, Angiotensin receptor blockers, Angiotensin converting enzyme inhibitors, Covid-19.

Cite This Article:

Please cite this article in press Syed Yasir Hussain and Ihsanullah Khan., Investigation Of Clinical Parameters Of Patients Admitted With Covid-19 Pneumonia And Medications Used To Treat Their Co – Morbidities.., Indo Am. J. P. Sci, 2021; 08(05).

Number of Downloads : 10

References:

1. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19), Indian J Pediatr. 2020; 87(4): 281-286. https://doi.org/10.1007/s12098-020-03263-6
2. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-879.
3. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ and van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis., J Pathol. 2004;203(2):631-637. https://doi.org/10.1002/path.1570
4. Watkins J. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 2020;368:m810. https://doi.org/10.1136/bmj.m810
5. Sodhi M and Etminan M. Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?. Chest. 2020;S0012- 3692(20):30572-30579. https://doi.org/10.1016/j.chest.2020.03.040
6. Mukesh T, Mamta P, Bharat N, Rai H and Bhattarai B. Evaluation of lung infiltration score to predict postural hypoxemia in ventilated acute respiratory distress syndrome patients and the lateralization of skin pressure sore Indian Journal of Medical Sciences Volume. 2009; 63(9):392-401. https://doi.org/10.4103/0019-5359.56110
7. Wang Q, Ma J, Jiang Z and Ming L. Prognostic Value of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio in Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis. Int Angiol. 2018;37(1):4-11.
8. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients, Circ Res. 2005; 97(9):946-953. https://doi.org/10.1161/01.RES.0000187500.24964.7A
9. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011; 166(1-3):90-97. https://doi.org/10.1016/j.regpep.2010.09.005
10. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation. 2005; 111(20):2605-2610. https://doi.org/10.1161/CIRCULATIONAHA.104.510461
11. Ding W, Li X, Wu W, He H, Li Y, Gao L, et al. Aliskiren inhibits angiotensin II/angiotensin 1-7(Ang II/Ang1-7) signal pathway in rats with diabetic nephropathy. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018; 34(10):891-895.
12. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506-510. https://doi.org/10.1038/s41591-020-0822-7
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020. published online March 9, 2020.
14. Chen TL, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical Characteristics and Outcomes of Older Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China (2019): A Single-Centered, Retrospective Study. J Gerontol A Biol Sci Med Sci. 2020; 75(9): 1788-1795. https://doi.org/10.1093/gerona/glaa089
15. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Hand Q, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Ageing and disease. 2020; 11(2): 216-228. https://doi.org/10.14336/AD.2020.0228
16. Zheng YY, Ma YT, Zhang JY and Xie X. COVID 19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17: 2589-260. https://doi.org/10.1038/s41569-020-0360-5
17. Fang L, Karakiulakis G and Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21 https://doi.org/10.1016/S2213-2600(20)30116-8
18. Lai CC, Liu YH, Wang C-Y, Wang Y-H, Hsueh S-C, Yen M-Y, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths, J Microbiol Immunol Infect. 2020;53(3):404-412. https://doi.org/10.1016/j.jmii.2020.02.012
19. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med. 2020; 15: 34 https://doi.org/10.1186/s13020-020-00317-x
20. Amici C, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus, Antivir Ther. 2006; 11(8):1021-1030.
21. Tai FWD and McAlindon ME. NSAIDs and the Small Bowel. Curr Opin Gastroenterol. 2018;34(3):175-182. https://doi.org/10.1097/MOG.0000000000000427
22. Giuliano C, Wilhelm SM and Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012; 5:337-344. https://doi.org/10.1586/ecp.12.20
23. de Jonge PJF, Siersema PD, Van Breda SGJ, Van Zoest KPM, Bac DJ, Leeuwenburgh I, et al. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Aliment Pharmacol Ther. 2008; 28: 127-136. https://doi.org/10.1111/j.1365-2036.2008.03699.x
24. Sarzynski E, Puttarajappa C, Xie Y, Grover M and Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011